Show simple item record

dc.contributor.authorGregson, Celia L
dc.contributor.authorArmstrong, David J
dc.contributor.authorBowden, Jean
dc.contributor.authorCooper, Cyrus
dc.contributor.authorEdwards, John
dc.contributor.authorGittoes, Neil JL
dc.contributor.authorHarvey, Nicholas
dc.contributor.authorKanis, John
dc.contributor.authorLeyland, Sarah
dc.contributor.authorLow, Rebecca
dc.contributor.authorMcCloskey, Eugene
dc.contributor.authorMoss, Katie
dc.contributor.authorParker, Jane
dc.contributor.authorPaskins, Zoe
dc.contributor.authorPoole, Kenneth
dc.contributor.authorReid, David M
dc.contributor.authorStone, Mike
dc.contributor.authorThomson, Julia
dc.contributor.authorVine, Nic
dc.contributor.authorCompston, Juliet
dc.date.accessioned2022-05-19T15:00:29Z
dc.date.available2022-05-19T15:00:29Z
dc.date.issued2022-04-05
dc.date.submitted2021-12-20
dc.identifier.issn1862-3522
dc.identifier.others11657-022-01061-5
dc.identifier.other1061
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337309
dc.description.abstractUNLABELLED: The National Osteoporosis Guideline Group (NOGG) has revised the UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Accredited by NICE, this guideline is relevant for all healthcare professionals involved in osteoporosis management. INTRODUCTION: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013 and 2017. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. METHODS: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. RESULTS: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, and models of care for fracture prevention. Recommendations are made for training; service leads and commissioners of healthcare; and for review criteria for audit and quality improvement. CONCLUSION: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and by the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectPosition Paper
dc.subjectOsteoporosis
dc.subjectFracture
dc.subjectNOGG
dc.subjectGuideline
dc.titleUK clinical guideline for the prevention and treatment of osteoporosis.
dc.typeArticle
dc.date.updated2022-05-19T15:00:28Z
prism.issueIdentifier1
prism.publicationNameArch Osteoporos
prism.volume17
dc.identifier.doi10.17863/CAM.84722
dcterms.dateAccepted2022-01-03
rioxxterms.versionofrecord10.1007/s11657-022-01061-5
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.identifier.eissn1862-3514
pubs.funder-project-idNational Institute for Health Research (CS-2018-18-ST2-010)
cam.issuedOnline2022-04-05


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record